Drug Trial News

RSS

Recruitment for the Phase IIa clinical trial to assess CNS 7056 sedative completed by PAION

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the Phase IIa clinical trial assessing the new short-acting intravenous anesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract.

8 Sep 2009

Securities class action lawsuit filed against Repros Therapeutics

Feazell & Tighe, L.L.P. announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Texas on behalf of all persons or entities who purchased or otherwise acquired the common stock of Repros Therapeutics Inc. (“Repros” or the “Company”) (Nasdaq:RPRX), between July 1, 2009 and August 3, 2009, inclusive (the “Class Period”).

5 Sep 2009

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Human Genome Sciences, Inc. today announced publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence-based systemic lupus erythematosus (SLE) Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA (belimumab) in serologically active patients with SLE.

4 Sep 2009

Dilafor Phase II clinical trial completes

Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth.

4 Sep 2009

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company’s potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).

4 Sep 2009

Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immune response

Results from the first swine-flu vaccine trials taking place in Leicester reveal a strong immune response after just one dose.

4 Sep 2009

Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Thomas Weisel Partners 2009 Healthcare Conference in Boston.

4 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

NOXXON Pharma AG (NOXXON), clinical-stage developer of L-RNA based scaffolds (Spiegelmers®) that bind their targets conceptually similar to antibodies, announced today that the company was awarded a research grant from Germany’s Federal Ministry of Education and Research (BMBF) under the ministry’s small and medium enterprise innovation initiative (“KMU-Innovativ”).

3 Sep 2009

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

Study reports a potential new investigational therapy for skin cancer

A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.

3 Sep 2009

First swine-flu vaccine trials reveal strong immune response

Results from the first swine-flu vaccine trials taking place in Leicester reveal a strong immune response after just one dose.

3 Sep 2009

CORD I phase III clinical trial results of XIAFLEX published

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that The New England Journal of Medicine (NEJM) has published in its September 3rd edition, the Company's pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) a novel, first-in-class, biologic for the nonsurgical treatment of Dupuytren's contracture.

3 Sep 2009

New clinical trials to address the effectiveness of antimicrobial drugs

Scientists are addressing the threat of antimicrobial drug resistance by launching two new clinical trials aimed at prolonging the effectiveness of currently available antibacterial drugs. The concept underlying both studies: Less is more.

3 Sep 2009

Interim Phase II data of Cotara reveals signs of efficacy in GBM patients

Peregrine Pharmaceuticals, Inc. today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer.

3 Sep 2009

GDC-0449 inhibits the Hedgehog signaling pathway

The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.

3 Sep 2009

Avastin increases survival rates in recurrent glioblastoma affected patients

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.

3 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009

FDA approves Astepro nasal spray 0.15% for the treatment of the symptoms of seasonal allergies

The U.S. Food and Drug Administration (FDA) has approved Astepro (azelastine) nasal spray 0.15% for the treatment of the symptoms of seasonal and perennial allergic rhinitis.

2 Sep 2009

Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon

A groundbreaking new treatment for obesity is to begin clinical trials in January. Madrona Ventures Inc., an American publicly listed company (OTCBB:MDRV), has acquired the treatment's European patent and the pending American patent application.

2 Sep 2009

Drug Trial News

Recruitment for the Phase IIa clinical trial to assess CNS 7056 sedative completed by PAION

Securities class action lawsuit filed against Repros Therapeutics

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Dilafor Phase II clinical trial completes

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immune response

Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Results of Phase 2 rheumatoid arthritis clinical trial announced

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Study reports a potential new investigational therapy for skin cancer

First swine-flu vaccine trials reveal strong immune response

CORD I phase III clinical trial results of XIAFLEX published

New clinical trials to address the effectiveness of antimicrobial drugs

Interim Phase II data of Cotara reveals signs of efficacy in GBM patients

GDC-0449 inhibits the Hedgehog signaling pathway

Avastin increases survival rates in recurrent glioblastoma affected patients

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

FDA approves Astepro nasal spray 0.15% for the treatment of the symptoms of seasonal allergies

Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News